Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634162 | 0.88 | GRIN2B (0.39) | GRIN2BFYNQPCTLQPCTDRD2 | |
| SCHEMBL12633848 | 0.87 | QPCT (0.44) | NPY1RQPCTLQPCTDRD2POLB | |
| SCHEMBL12633830 | 0.84 | QPCTL (0.43) | GRIN2BFYNQPCTLQPCTDRD2 | |
| Hydrochloric Acid SCHEMBL1876986 | 0.83 | GRIN2B (0.41) | GRIN2BNPY1RFYNQPCTLQPCT | |
| SCHEMBL12634159 | 0.82 | PTGDR2 (0.36) | QPCTPOLBFFAR1KMT2A | |
| Trifluoroacetic Acid SCHEMBL1874615 | 0.81 | SLC2A1 (0.38) | NPY1RQPCTPRMT5CASP6FFAR1 | |
| Trifluoroacetic Acid SCHEMBL1875567 | 0.81 | SLC2A1 (0.38) | NPY1RQPCTPRMT5CASP6FFAR1 | |
| SCHEMBL13137053 | 0.81 | GRIN2B (0.41) | GRIN2BFYNQPCTLQPCTPOLB | |
| SCHEMBL14548043 | 0.80 | QPCT (0.44) | FYNQPCTLQPCTDRD2 | |
| Trifluoroacetic Acid SCHEMBL1875560 | 0.79 | SLC2A1 (0.40) | GRIN2BFYNDRD2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | OPRK1, OPRL1, OPRD1 | GRIN2B 288/4885NPY1R 58/4885FYN 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.